Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01121562
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date July 2010
Completion date November 2013

See also
  Status Clinical Trial Phase
Recruiting NCT03053999 - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Completed NCT02586844 - Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Completed NCT02842749 - Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Phase 4
Unknown status NCT01381822 - Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Phase 1
Completed NCT01384617 - Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy N/A
Completed NCT02841865 - Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Completed NCT02685553 - Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project Phase 1
Completed NCT02282059 - The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Terminated NCT01648465 - Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Phase 2
Terminated NCT02110563 - Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1
Completed NCT02125929 - Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms N/A